Role of nutrient-sensing signals in the pathogenesis of diabetic nephropathy

BioMed Research International

Volumn 2014, Issue , 2014, Pages

  Kume, Shinji ^a   Koya, Daisuke ^b   Uzu, Takashi ^a   Maegawa, Hiroshi ^a  

^a SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

^b KANAZAWA MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADENYLATE KINASE; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; SIRTUIN 1; AMP-ACTIVATED PROTEIN KINASE KINASE; MECHANISTIC TARGET OF RAPAMYCIN COMPLEX 1; MULTIPROTEIN COMPLEX; PROTEIN KINASE; SIRT1 PROTEIN, HUMAN; TARGET OF RAPAMYCIN KINASE;

AUTOPHAGY; CALORIC RESTRICTION; CELL ORGANELLE; DIABETIC NEPHROPATHY; DIET THERAPY; HUMAN; KIDNEY; KIDNEY TUBULE CELL; NONHUMAN; NUTRITIONAL STATUS; OBESITY; PATHOGENESIS; PODOCYTE; PROTEIN RESTRICTION; REVIEW; SIGNAL TRANSDUCTION; ANIMAL; DIABETIC NEPHROPATHIES; FOOD; GENETICS; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY;

ANIMALS; AUTOPHAGY; DIABETIC NEPHROPATHIES; FOOD; HUMANS; METABOLIC NETWORKS AND PATHWAYS; MULTIPROTEIN COMPLEXES; PODOCYTES; PROTEIN KINASES; SIRTUIN 1; TOR SERINE-THREONINE KINASES;

EID: 84912123766     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2014/315494     Document Type: Review

References (64)

1. R. Zoncu, A. Efeyan, and D. M. Sabatini, "MTOR: from growth signal integration to cancer, diabetes and ageing, " Nature Reviews Molecular Cell Biology, vol. 12, no. 1, pp. 21-35, 2011.
2. K. E. Wellen and C. B. Thompson, "Cellular metabolic stress: considering how cells respond to nutrient excess, " Molecular Cell, vol. 40, no. 2, pp. 323-332, 2010.
3. G. R. Steinberg and B. E. Kemp, "AMPK in health and disease, " Physiological Reviews, vol. 89, no. 3, pp. 1025-1078, 2009.
4. S. Imai and L. Guarente, "Ten years of NAD-dependent SIR2 family deacetylases: implications for metabolic diseases, " Trends in Pharmacological Sciences, vol. 31, no. 5, pp. 212-220, 2010.
5. L. Guarente, "Sirtuins, aging, and medicine, " The New England Journal of Medicine, vol. 364, no. 23, pp. 2235-2244, 2011.
6. T. B. Huber, G. Walz, and E. W. Kuehn, "MTOR and rapamycin in the kidney: signaling and therapeutic implications beyond immunosuppression, " Kidney International, vol. 79, no. 5, pp. 502-511, 2011.
7. C. Hao and V. H. Haase, "Sirtuins and their relevance to the kidney, " Journal of the American Society of Nephrology, vol. 21, no. 10, pp. 1620-1627, 2010.
8. K. R. Hallows, P. F. Mount, N. M. Pastor-Soler, and D. A. Power, "Role of the energy sensorAMP-activated protein kinase in renal physiology and disease, " The American Journal of Physiology-Renal Physiology, vol. 298, no. 5, pp. F1067-F1077, 2010.
9. S. Kume, M. C. Thomas, and D. Koya, "Nutrient sensing, autophagy, and diabetic nephropathy, " Diabetes, vol. 61, no. 1, pp. 23-29, 2012.
10. C. Baltzer, S. K. Tiefenbock, and C. Frei, "Mitochondria in response to nutrients and nutrient-sensitive pathways, " Mitochondrion, vol. 10, no. 6, pp. 589-597, 2010.
11. Y. Tanaka, S. Kume, S. Araki et al., "Fenofibrate, a PPARα agonist, has renoprotective effects in mice by enhancing renal lipolysis, " Kidney International, vol. 79, no. 8, pp. 871-882, 2011.
12. I. Hwang, J. Lee, J. Y. Huh et al., "Catalase deficiency accelerates diabetic renal injury through peroxisomal dysfunction, " Diabetes, vol. 61, no. 3, pp. 728-738, 2012.
13. M. T. Lindenmeyer, M. P. Rastaldi, M. Ikehata et al., "Proteinuria and hyperglycemia induce endoplasmic reticulum stress, " Journal of theAmerican Society of Nephrology, vol. 19, no. 11, pp. 2225-2236, 2008.
14. J. M. Forbes, M. T. Coughlan, and M. E. Cooper, "Oxidative stress as amajor culprit in kidney disease in diabetes, " Diabetes, vol. 57, no. 6, pp. 1446-1454, 2008.
15. N. Mizushima and M. Komatsu, "Autophagy: renovation of cells and tissues, " Cell, vol. 147, no. 4, pp. 728-741, 2011.
16. S. Kume, T. Uzu, K. Horiike et al., "Calorie restriction enhances cell adaptation to hypoxia through Sirt1-dependent mitochondrial autophagy in mouse aged kidney, " Journal of Clinical Investigation, vol. 120, no. 4, pp. 1043-1055, 2010.
17. J. Kim, M. Kundu, B. Viollet, and K. Guan, "AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1, " Nature Cell Biology, vol. 13, no. 2, pp. 132-141, 2011.
18. J. K. Chen, G. Thomas, S. C. Kozma, and R. C. Harris, "S6 kinase 1 knockout inhibits uninephrectomy-or diabetes-induced renal hypertrophy, " The American Journal of Physiology-Renal Physiology, vol. 297, no. 3, pp. F585-F593, 2009.
19. K. Sataranatarajan, M. M. Mariappan, J. L. Myung et al., "Regulation of elongation phase of mRNA translation in diabetic nephropathy: amelioration by rapamycin, " The American Journal of Pathology, vol. 171, no. 6, pp. 1733-1742, 2007.
20. M. Sakaguchi, M. Isono, K. Isshiki, T. Sugimoto, D. Koya, and A. Kashiwagi, "Inhibition of mTOR signaling with rapamycin attenuates renal hypertrophy in the early diabetic mice, " Biochemical and Biophysical Research Communications, vol. 340, no. 1, pp. 296-301, 2006.
21. S. Wittmann, C. Daniel, A. Stief, R. Vogelbacher, K. Amann, and C. Hugo, "Long-term treatment of sirolimus but not cyclosporine ameliorates diabetic nephropathy in the rat, " Transplantation, vol. 87, no. 9, pp. 1290-1299, 2009.
22. H. Mori, K. Inoki, K. Masutani et al., "The mTOR pathway is highly activated in diabetic nephropathy and rapamycin has a strong therapeutic potential, " Biochemical and Biophysical Research Communications, vol. 384, no. 4, pp. 471-475, 2009.
23. Y. Yang, J. Wang, L. Qin et al., "Rapamycin prevents early steps of the development of diabetic nephropathy in rats, " American Journal of Nephrology, vol. 27, no. 5, pp. 495-502, 2007.
24. N. Lloberas, J. M. Cruzado, M. Franquesa et al., "Mammalian target of rapamycin pathway blockade slows progression of diabetic kidney disease in rats, " Journal of the American Society of Nephrology, vol. 17, no. 5, pp. 1395-1404, 2006.
25. K. Nagai, T. Matsubara, A. Mima et al., "Gas6 induces Akt/mTOR-mediated mesangial hypertrophy in diabetic nephropathy, " Kidney International, vol. 68, no. 2, pp. 552-561, 2005.
26. K. Yamahara, S. Kume, D. Koya et al., "Obesity-mediated autophagy insufficiency exacerbates proteinuria-induced tubulointerstitial lesions, " Journal of the American Society ofNephrology, vol. 24, no. 11, pp. 1769-1781, 2013.
27. K. Inoki, H. Mori, J. Wang et al., "mTORC1 activation in podocytes is a critical step in the development of diabetic nephropathy in mice, " Journal of Clinical Investigation, vol. 121, no. 6, pp. 2181-2196, 2011.
28. M. Godel, B. Hartleben, N. Herbach et al., "Role of mTOR in podocyte function and diabetic nephropathy in humans and mice, " Journal of Clinical Investigation, vol. 121, no. 6, pp. 2197-2209, 2011.
29. C. Velagapudi, B. S. Bhandari, S. Abboud-Werner, S. Simone, H. E. Abboud, and S. L. Habib, "The tuberin/mTOR pathway promotes apoptosis of tubular epithelial cells in diabetes, " Journal of theAmerican Society of Nephrology, vol. 22, no. 2, pp. 262-273, 2011.
30. P. Cravedi, P. Ruggenenti, and G. Remuzzi, "Sirolimus for calcineurin inhibitors in organ transplantation: contra, " Kidney International, vol. 78, no. 11, pp. 1068-1074, 2010.
31. T. Yamauchi, J. Kamon, Y. Minokoshi et al., "Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase, " Nature Medicine, vol. 8, no. 11, pp. 1288-1295, 2002.
32. P. G. Cammisotto, I. Londono, D. Gingras, and M. Bendayan, "Control of glycogen synthase through ADIPOR1-AMPK pathway in renal distal tubules of normal and diabetic rats, " The American Journal of Physiology-Renal Physiology, vol. 294, no. 4, pp. F881-F889, 2008.
33. Z. Guo and Z. Zhao, "Effect of N-acetylcysteine on plasma adiponectin and renal adiponectin receptors in streptozotocininduced diabetic rats, " European Journal of Pharmacology, vol. 558, no. 1-3, pp. 208-213, 2007.
34. M. Lee, D. Feliers, M. M. Mariappan et al., "A role for AMPactivated protein kinase in diabetes-induced renal hypertrophy, " American Journal of Physiology:Renal Physiology, vol. 292, no. 2, pp. F617-F627, 2007.
35. M. Kitada, S. Kume, N. Imaizumi, and D. Koya, "Resveratrol improves oxidative stress and protects against diabetic nephropathy through normalization of Mn-SOD dysfunction in AMPK/SIRT1-independent pathway, " Diabetes, vol. 60, no. 2, pp. 634-643, 2011.
36. S. Kume, T. Uzu, S. Araki et al., "Role of altered renal lipid metabolism in the development of renal injury induced by a high-fat diet, " Journal of theAmericanSociety of Nephrology, vol. 18, no. 10, pp. 2715-2723, 2007.
37. L. L. Dugan, Y. H. You, S. S. Ali et al., "AMPK dysregulation promotes diabetes-related reduction of superoxide and mitochondrial function, " Journal of Clinical Investigation, vol. 123, no. 11, pp. 4888-4899, 2013.
38. K. Sharma, S. RamachandraRao, G. Qiu et al., "Adiponectin regulates albuminuria and podocyte function in mice, " Journal of Clinical Investigation, vol. 118, no. 5, pp. 1645-1656, 2008.
39. P. G. Cammisotto and M. Bendayan, "Adiponectin stimulates phosphorylation of AMP-activated protein kinase α in renal glomeruli, " Journal of Molecular Histology, vol. 39, no. 6, pp. 579-584, 2008.
40. K. Tikoo, K. Singh, D. Kabra, V. Sharma, and A. Gaikwad, "Change in histone H3 phosphorylation, MAPkinase p38, SIR 2 and p53 expression by resveratrol in preventing streptozotocin induced type I diabetic nephropathy, " Free Radical Research, vol. 42, no. 4, pp. 397-404, 2008.
41. C. Li, F. Cai, Y. Yang et al., "Tetrahydroxystilbene glucoside ameliorates diabetic nephropathy in rats: involvement of SIRT1 and TGF-β1 pathway, " European Journal of Pharmacology, vol. 649, no. 1-3, pp. 382-389, 2010.
42. H. Y. Cohen, C. Miller, K. J. Bitterman et al., "Calorie restriction promotes mammalian cell survival by inducing the SIRT1 deacetylase, " Science, vol. 305, no. 5682, pp. 390-392, 2004.
43. K. Hasegawa, S. Wakino, P. Simic et al., "Renal tubular Sirt1 attenuates diabetic albuminuria by epigenetically suppressing Claudin-1 overexpression in podocytes, " Nature Medicine, vol. 19, no. 11, pp. 1496-1504, 2013.
44. W. He, Y. Wang, M. Zhang et al., "Sirt1 activation protects the mouse renal medulla from oxidative injury, " Journal of Clinical Investigation, vol. 120, no. 4, pp. 1056-1068, 2010.
45. K. Hasegawa, S. Wakino, K. Yoshioka et al., "Kidney-specific overexpression of Sirt1 protects against acute kidney injury by retaining peroxisome function, " Journal of Biological Chemistry, vol. 285, no. 17, pp. 13045-13056, 2010.
46. J. Li, X. Qu, S. D. Ricardo, J. F. Bertram, and D. J. Nikolic-Paterson, "Resveratrol inhibits renal fibrosis in the obstructed kidney: potential role in deacetylation of Smad3, " The American Journal of Pathology, vol. 177, no. 3, pp. 1065-1071, 2010.
47. S. Kume, M. Haneda, K. Kanasaki et al., "Silent information regulator 2 (SIRT1) attenuates oxidative stress-induced mesangial cell apoptosis via p53 deacetylation, " Free Radical Biology and Medicine, vol. 40, no. 12, pp. 2175-2182, 2006.
48. S. Kume, M. Haneda, K. Kanasaki et al., "SIRT1 inhibits transforming growth factor β-induced apoptosis in glomerular mesangial cells via Smad7 deacetylation, " Journal of Biological Chemistry, vol. 282, no. 1, pp. 151-158, 2007.
49. J. A. Funk, S. Odejinmi, and R. G. Schnellmann, "SRT1720 induces mitochondrial biogenesis and rescues mitochondrial function after oxidant injury in renal proximal tubule cells, " Journal of Pharmacology and Experimental Therapeutics, vol. 333, no. 2, pp. 593-601, 2010.
50. S.-J. Lin, P.-A. Defossez, and L. Guarente, "Requirement of NAD and SIR2 for life-span extension by calorie restriction in saccharomyces cerevisiae, " Science, vol. 289, no. 5487, pp. 2126-2128, 2000.
51. M. Kitada, A. Takeda, T. Nagai, H. Ito, K. Kanasaki, and D. Koya, "Dietary restriction ameliorates diabetic nephropathy through anti-inflammatory effects and regulation of the autophagy via restoration of sirt1 in diabetic wistar fatty (fa/fa) rats: a model of type 2 diabetes, " Experimental Diabetes Research, vol. 2011, Article ID 908185, 11 pages, 2011.
52. J. Sieber, M. T. Lindenmeyer, K. Kampe et al., "Regulation of podocyte survival and endoplasmic reticulum stress by fatty acids, " The American Journal of Physiology-Renal Physiology, vol. 299, no. 4, pp. F821-F829, 2010.
53. A. V. Cybulsky, "Endoplasmic reticulum stressin proteinuric kidney disease, " Kidney International, vol. 77, no. 3, pp. 187-193, 2010.
54. G. Kroemer, G. Marino, and B. Levine, "Autophagy and the integrated stress response, " Molecular Cell, vol. 40, no. 2, pp. 280-293, 2010.
55. I. H. Lee, L. Cao, R. Mostoslavsky et al., "A role for the NADdependent deacetylase Sirt1 in the regulation of autophagy, " Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 9, pp. 3374-3379, 2008.
56. J. Farre, R. Manjithaya, R. D. Mathewson, and S. Subramani, "PpAtg30 tags peroxisomes for turnover by selective autophagy, " Developmental cell, vol. 14, no. 3, pp. 365-376, 2008.
57. B. Hartleben, M. Godel, C. Meyer-Schwesinger et al., "Autophagy influences glomerular disease susceptibility and maintains podocyte homeostasis in aging mice, " Journal of Clinical Investigation, vol. 120, no. 4, pp. 1084-1096, 2010.
58. T. Kimura, Y. Takabatake, A. Takahashi et al., "Autophagy protects the proximal tubule fromdegeneration and acute ischemic injury, " Journal of the American Society of Nephrology, vol. 22, no. 5, pp. 902-913, 2011.
59. M. Jiang, K. Liu, J. Luo, and Z. Dong, "Autophagy is a renoprotective mechanism during in vitro hypoxia and in vivo ischemia-reperfusion injury, " American Journal of Pathology, vol. 176, no. 3, pp. 1181-1192, 2010.
60. S. Periyasamy-Thandavan, M. Jiang, Q. Wei, R. Smith, X. Yin, and Z. Dong, "Autophagy is cytoprotective during cisplatin injury of renal proximal tubular cells, " Kidney International, vol. 74, no. 5, pp. 631-640, 2008.
61. A. Takahashi, T. Kimura, Y. Takabatake et al., "Autophagy guards against cisplatin-induced acute kidney injury, " The American Journal of Pathology, vol. 180, no. 2, pp. 517-525, 2012.
62. K. L. Stanhope, J. M. Schwarz, N. L. Keim et al., "Consuming fructose-sweetened, not glucose-sweetened, beverages increases visceral adiposity and lipids and decreases insulin sensitivity in overweight/obese humans, " Journal of Clinical Investigation, vol. 119, no. 5, pp. 1322-1334, 2009.
63. T. J. Wang, M. G. Larson, R. S. Vasan et al., "Metabolite profiles and the risk of developing diabetes, " Nature Medicine, vol. 17, no. 4, pp. 448-453, 2011.
64. E. P. Rhee, S. Cheng, M. G. Larson et al., "Lipid profiling identifies a triacylglycerol signature of insulin resistance and improves diabetes prediction in humans, " Journal of Clinical Investigation, vol. 121, no. 4, pp. 1402-1411, 2011.